Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Accumulated Expenses data on file, last reported at $48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 31.62% year-over-year to $48.4 million; the trailing twelve-month figure through Mar 2026 stood at $48.4 million (down 31.62% YoY), and the FY2025 full-year result was $66.5 million, up 1.64% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $48.4 million, down from $66.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $122.6 million in Q1 2023 and bottomed at $48.4 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $79.3 million (2025), against an average of $87.9 million.
• The widest annual swing landed in 2023, when Accumulated Expenses jumped 57.69%; it then slumped 51.13% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $114.7 million in 2022, then retreated by 4.05% to $110.1 million in 2023, then tumbled by 40.58% to $65.4 million in 2024, then climbed by 1.64% to $66.5 million in 2025, then dropped by 27.21% to $48.4 million in 2026.
• The last three Accumulated Expenses figures came in at $48.4 million (Q1 2026), $66.5 million (Q4 2025), and $79.3 million (Q3 2025), per Business Quant data.

Peer Comparison